Results 121 to 130 of about 2,581 (172)

In vitro assays identified thiohydantoins with anti-trypanosomatid activity and molecular modelling studies indicated possible selective CYP51 inhibition. [PDF]

Sci Rep
Camargo PG, Suzukawa HT, Pereira PML, Silva ML, Macedo F, Albuquerque MG, Rodrigues CR, Yamada-Ogatta SF, da Silva Lima CH, Bispo MLF.   +9 more
europepmc   +1 more source

Synthesis and Biological Evaluation of 4‑(4-Nitrophenyl)‑1<i>H</i>‑1,2,3-triazole Derivatives as Antitrypanosomal Agents. [PDF]

ACS Omega
Oliveira FC, Zamoner LOB, Baruffi MD, Augusto BS, Vaidergorn MM, Nonato MC, Bologna TS, da Silva MV, Carvalho I.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Novel antitrypanosomal agents

Expert Opinion on Investigational Drugs, 2005
Trypanosomes are the causative agents of Chagas' disease in Central and South America and sleeping sickness in sub-Saharan Africa. The current chemotherapy of the human trypanosomiases relies on only six drugs, five of which were developed > 30 years ago.
Steverding, Dietmar, Tyler, Kevin M.
openaire   +3 more sources

Antitrypanosomal Activity of Phosphonylmethoxyalkylpurines

The Journal of Parasitology, 1994
Phosphonylmethoxyalkylpurines and -pyrimidines exhibit potent activity against a broad spectrum of DNA viruses. We evaluated some of these nucleotide analogues for antitrypanosomal activity in vitro and in mice. The most active compounds were (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine (HPMPA) and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-
R, Kaminsky, E, Zweygarth, E, De Clercq
openaire   +2 more sources

Bistacrines as potential antitrypanosomal agents

Bioorganic & Medicinal Chemistry, 2017
Human African Trypanosomiasis (HAT) is caused by two subspecies of the genus Trypanosoma, namely Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. The disease is fatal if left untreated and therapy is limited due to only five non-adequate drugs currently available. In preliminary studies, dimeric tacrine derivatives were found to inhibit
Ines, Schmidt, Sarah, Göllner, Antje, Fuß, August, Stich, Anna, Kucharski, Tanja, Schirmeister, Elena, Katzowitsch, Heike, Bruhn, Alexandra, Miliu, R Luise, Krauth-Siegel, Ulrike, Holzgrabe   +10 more
openaire   +2 more sources

Antitrypanosomal Therapy for Chronic Chagas' Disease

New England Journal of Medicine, 2011
A 42-year-old woman presents after donating blood and receiving a report that she is positive for Chagas' disease. Chagas' disease is caused by a parasite and is endemic in many parts of Latin America.
Facundo, Garcia-Bournissen, Jaime, Altcheh   +1 more
openaire   +5 more sources

Antileishmanial and antitrypanosomal drug identification

Emerging Topics in Life Sciences, 2017
Although the treatments for human African trypanosomiasis (HAT), leishmaniasis and Chagas disease (CD) still rely on drugs developed several decades ago, there has been significant progress in the identification, development and use of novel drugs and formulations. Notably, there are now two drugs in clinical trial for HAT, fexinidazole and acoziborole;
Simon L, Croft, Eric, Chatelain, Michael P, Barrett   +2 more
openaire   +2 more sources

Antitrypanosomal and Antileishmanial Activities

2018
The so-called neglected tropical diseases, which are endemic in 149 tropical and subtropical countries, affect more than 1 billion people annually, including 875 million children in developing economies. These diseases are responsible for over 500,000 deaths per year and are characterized by long-term disability and severe pain.
Sanchez Alberti, Andrés, Cerny, Natacha, Bivona, Augusto Ernesto, Cazorla, Silvia Ines   +3 more
openaire   +2 more sources